At Novo Nordisk, we are interested in innovative compounds and technologies that address unmet medical needs and have the potential to improve the lives of people with serious chronic diseases. We are interested in development stages from target identification to clinical stage.
A partnership with Novo Nordisk is a collaborative partnership, where we work together and combine our capabilities to create new human therapeutics, scientific insights, or enabling technologies. We have used a number of collaboration models in the past, and we are open and flexible to explore new modes of collaboration to build long-term and fruitful alliances based on trust.
Novo Nordisk takes part in a new European collaborative research project Hypo-RESOLVE - an international consortium of experts from academia, industry and civil society. The project aims to provide evidence-based insights into all aspects of hypoglycaemia to better understand its impact on people living with diabetes.
Collaborations with external partners are essential to our R&D efforts at Novo Nordisk. We constantly seek new partnerships with leading individual experts and research teams within biotechnology, academia, as well as with other pharmaceutical companies.
Novo Nordisk is always interested in gaining access to the latest relevant innovation and research, and we regularly license intellectual property rights to new technologies or assets from leading external partners. License agreements can be structured in many ways, but our objective is always to expand the Novo Nordisk pipeline with new exciting assets and/or to support projects with critical technologies.
Novo Nordisk will also consider the acquisition of small start-ups or parts of biotech companies in cases where there is a good match in complementary expertise and mutual interest.
"We have the skills and experience within drug and device development to turn your ideas into treatment solutions for patients."
Vice President, Search & Evaluation